



$AP-2\alpha/\beta$ Polyclonal Antibody

Catalog No BYab-01531 Isotype IgG Reactivity Human;Mouse;Rat Applications WB;IHC;IF;ELISA Gene Name TFAP2A/TFAP2B Protein Name Transcription factor AP-2-alpha/beta Immunogen The antiserum was produced against synthesized peptide derived from human AP-2. AA range:388-437 Specificity AP-2α/β Polyclonal Antibody detects endogenous levels of AP-2α/β protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000. IF 1:50-200 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP2-al		
Reactivity Human;Mouse;Rat Applications WB;IHC;IF;ELISA Gene Name TFAP2A/TFAP2B Protein Name Transcription factor AP-2-alpha/beta Immunogen The antiserum was produced against synthesized peptide derived from human AP-2. AA range:388-437 Specificity AP-2α/β Polyclonal Antibody detects endogenous levels of AP-2α/β protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000 IF 1:50-200 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP2-alpha; AP2-alpha; AP2-2; transcription factor; Activating enhancer-bindi group antibodic products and penhancer-bindi Observed Band 49kD Cell Pathway Nucleus. Tissue Specificity Prostate, Teratocarcinoma, alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiocoulofacial syndrome. BOFS i	Catalog No	BYab-01531
Applications WB;IHC;IF;ELISA Gene Name TFAP2A/TFAP2B Protein Name Transcription factor AP-2-alpha/beta Immunogen The antiserum was produced against synthesized peptide derived from human AP-2. AA range:388-437 Specificity AP-2α/β Polyclonal Antibody detects endogenous levels of AP-2α/β protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000 IF 1:50-200 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP2-transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; ACtivating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus. Tissue Specificity Prostate, Teratocarcinoma, alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiocculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies; growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial dorder with variable BOFS is a rare autosomal dominant cleft palate craniforacial disorder with variable	Isotype	IgG
Gene Name TFAP2A/TFAP2B Protein Name Transcription factor AP-2-alpha/beta Immunogen The antiserum was produced against synthesized peptide derived from human AP-2. AA range:388-437 Specificity AP-2α/β Polyclonal Antibody detects endogenous levels of AP-2α/β protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000. IF 1:50-200 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP2-transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus . Tissue Specificity Prostate, Teratocarcinoma, Function alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiocculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts wi	Reactivity	Human;Mouse;Rat
Protein Name Transcription factor AP-2-alpha/beta Immunogen The antiserum was produced against synthesized peptide derived from human AP-2. AA range:388-437 Specificity AP-2α/β Polyclonal Antibody detects endogenous levels of AP-2α/β protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000 IF 1:50-200 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus . Tissue Specificity Prostate, Teratocarcinoma, alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchicoculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies; growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous bran	Applications	WB;IHC;IF;ELISA
Immunogen The antiserum was produced against synthesized peptide derived from human AP-2. AA range:388-437 Specificity AP-2α/β Polyclonal Antibody detects endogenous levels of AP-2α/β protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000 IF 1:50-200 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus Tissue Specificity Prostate, Teratocarcinoma, alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchicoculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies; growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cleft with variable BOFS is a rare autosomal dominant cleft plate craniofacial disorder with variable	Gene Name	TFAP2A/TFAP2B
AP-2. AA range:388-437 Specificity AP-2α/β Polyclonal Antibody detects endogenous levels of AP-2α/β protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000 IF 1:50-200 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindil Observed Band 49kD Cell Pathway Nucleus. Tissue Specificity Prostate, Teratocarcinoma, alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchical clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemanglomatous branchical cleft systyndrome. BOFS is a rare autosomal dominant cleft palate candidated and confirmation duct, and premature aging or lip pseudocleft-hemanglomatous branchical cleft systyndrome.	Protein Name	Transcription factor AP-2-alpha/beta
Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit,IgG The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000 IF 1:50-200 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus Tissue Specificity Prostate, Teratocarcinoma, alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiocoulofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or il pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Immunogen	
Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000 IF 1:50-200 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus Tissue Specificity Prostate, Teratocarcinoma, alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchioaculofacial syndrome (BOFS) [Mill 113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Specificity	AP-2 α/β Polyclonal Antibody detects endogenous levels of AP-2 α/β protein.
Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000 IF 1:50-200 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus Tissue Specificity Prostate, Teratocarcinoma, alternative products:Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [Mil:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Formulation	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
affinity-chromatography using epitope-specific immunogen. Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000 IF 1:50-200 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus . Tissue Specificity Prostate, Teratocarcinoma, alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Source	Polyclonal, Rabbit,IgG
Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus . Tissue Specificity Prostate, Teratocarcinoma, Function alternative products:Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Purification	·
Purity ≥90% Storage Stability -20°C/1 year Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus . Tissue Specificity Prostate,Teratocarcinoma, Function alternative products:Experimental confirmation may be lacking for some isoforms, disease:Defects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Dilution	WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000 IF 1:50-200
Storage Stability -20°C/1 year TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus . Tissue Specificity Prostate, Teratocarcinoma, Function alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Concentration	1 mg/ml
Synonyms TFAP2A; AP2TF; TFAP2; Transcription factor AP-2-alpha; AP2-alpha; AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus Prostate, Teratocarcinoma, alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Purity	≥90%
transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating enhancer-bindi Observed Band 49kD Cell Pathway Nucleus . Tissue Specificity Prostate, Teratocarcinoma, Function alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Storage Stability	-20°C/1 year
Cell Pathway Nucleus . Tissue Specificity Prostate, Teratocarcinoma, alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Synonyms	transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2; AP-2; TFAP2B; Transcription factor AP-2-beta; AP2-beta; Activating
Tissue Specificity Prostate, Teratocarcinoma, alternative products: Experimental confirmation may be lacking for some isoforms, disease: Defects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Observed Band	49kD
Function alternative products:Experimental confirmation may be lacking for some isoforms, disease:Defects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Cell Pathway	Nucleus .
isoforms,disease:Defects in TFAP2A are the causé of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable	Tissue Specificity	Prostate,Teratocarcinoma,

Nanjing BYabscience technology Co.,Ltd

网址: www.njbybio.com 官方热线: 025-5229-8998 监督电话: 15950492658




国内优质抗体供应商 精准的 WB 检测服务 24H 在线服务,欢迎咨询




	characteristic facial appearance (malformed pinnae, oral clefts), and, less commonly, renal and ectodermal (dental and hair) anomalies.,domain:The WW-binding motif mediates interaction with WWOX.,function:Sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes. AP-2 factors bind to
Background	transcription factor AP-2 alpha(TFAP2A) Homo sapiens The protein encoded by this gene is a transcription factor that binds the consensus sequence 5'-GCCNNNGGC-3'. The encoded protein functions as either a homodimer or as a heterodimer with similar family members. This protein activates the transcription of some genes while inhibiting the transcription of others. Defects in this gene are a cause of branchiooculofacial syndrome (BOFS). Three transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Dec 2009],
matters needing attention	Avoid repeated freezing and thawing!
Usage suggestions	This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

Products Images




Western Blot analysis of various cells using AP- $2\alpha/\beta$ Polyclonal Antibody cells nucleus extracted by Minute TM Cytoplasmic and Nuclear Fractionation kit (SC-003,Inventbiotech,MN,USA).




Immunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue, using AP-2 Antibody. The picture on the right is blocked with the synthesized peptide.

Nanjing BYabscience technology Co.,Ltd

网址: www.njbybio.com 官方热线: 025-5229-8998 监督电话: 15950492658







Western blot analysis of lysates from COLO205 cells, using AP-2 Antibody. The lane on the right is blocked with the synthesized peptide.

网址: www.njbybio.com 官方热线: 025-5229-8998 监督电话: 15950492658